Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

Ann: Incannex Presentation - Dr Sud Agarwal - CMO, page-51

First 51 Last

Share
Profile

Follow
asxwade

205 Posts.

88

05/10/19

05:14

Post #: 40736699
Share

Originally posted by MickeyMantle536: ↑

I don’t have any issue with what you’ve stated, and I’m happy to address your questions.

Cannvalate (which was founded by Dr Sud Agarwal, now IHL’s CMO) committed in excess of $3 million to the current four clinical trials. IHL’s expenditure is capped at a maximum of $80,000 plus GST per trial. The percentage paid by Cannvalate is irrelevant IMO, it may be more or less than 90% but what is important is IHL have a capped expense and retain 100% of the IP.

IHL have some revenue from dental devices and will naturally improve on this front with CBD oil sales under the SAS. While the company is probably not far off break-even, I agree with you that successful biotechs are more likely acquired and that’s exactly why I’m invested.

IMO the current revenue is only important from the perspective of covering some of the company’s overheads. Otherwise it’s irrelevant, and possibly a curse because of the discussion that evolves around whether the revenue is growing and by how much. I couldn’t give two hoots if they made zero revenue.

Investors will be rewarded by the IP generation not small scale revenues. The key is creating IP in >$1 billion markets that have no competitive pharmaceutical options. These products stand a good chance of being adopted by the PBS and then (at least IMO) you will see big pharma write a big cheque. This is an age tested paradigm with a predictable exit.

The most interesting observation is the clinical opportunities in Australia under the SAS which very few investors appear to have worked out. And that gem is something I won’t be sharing atm but it’s information that everyone can find with some time and effort... DYOR.

Expand

Thanks for your reply. Apart from the 80 grand per trial, IHL has granted Cannvalate 120 MILLION options. These options far outway the cash expenditure.. Im not offering a personal opinion on this, but rather would like to know if current holders on board with this?

IHL Price at posting: 8.6¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

NRX

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

EVN

Evolution shares up 3% on quarterly results for June showing rise in gold production

FMG

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI